Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

450 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1-infected patients receiving abacavir in combination with HIV-1 protease inhibitors.
Wu H, Mellors J, Ruan P, McMahon D, Kelleher D, Lederman MM; CNAA2004 Study Investigators. Wu H, et al. Among authors: lederman mm. J Acquir Immune Defic Syndr. 2003 Aug 15;33(5):557-63. doi: 10.1097/00126334-200308150-00002. J Acquir Immune Defic Syndr. 2003. PMID: 12902798 Clinical Trial.
Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points.
Wu H, Kuritzkes DR, McClernon DR, Kessler H, Connick E, Landay A, Spear G, Heath-Chiozzi M, Rousseau F, Fox L, Spritzler J, Leonard JM, Lederman MM. Wu H, et al. Among authors: lederman mm. J Infect Dis. 1999 Apr;179(4):799-807. doi: 10.1086/314670. J Infect Dis. 1999. PMID: 10068574
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
Kuritzkes DR, Sevin A, Young B, Bakhtiari M, Wu H, St Clair M, Connick E, Landay A, Spritzler J, Kessler H, Lederman MM. Kuritzkes DR, et al. Among authors: lederman mm. J Infect Dis. 2000 Feb;181(2):491-7. doi: 10.1086/315244. J Infect Dis. 2000. PMID: 10669331 Clinical Trial.
Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial.
Collier AC, Kalish LA, Busch MP, Gernsheimer T, Assmann SF, Lane TA, Asmuth DM, Lederman MM, Murphy EL, Kumar P, Kelley M, Flanigan TP, McMahon DK, Sacks HS, Kennedy MS, Holland PV; Viral Activation Transfusion Study Group. Collier AC, et al. Among authors: lederman mm. JAMA. 2001 Mar 28;285(12):1592-601. doi: 10.1001/jama.285.12.1592. JAMA. 2001. PMID: 11268267 Clinical Trial.
Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy.
Wu H, Connick E, Kuritzkes DR, Landay A, Spritzler J, Zhang B, Spear GT, Kessler H, Lederman MM; ACTG 315 Team. Wu H, et al. Among authors: lederman mm. AIDS Res Hum Retroviruses. 2001 Sep 1;17(13):1231-40. doi: 10.1089/088922201750461285. AIDS Res Hum Retroviruses. 2001. PMID: 11559422 Clinical Trial.
Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation.
Calabrese LH, Lederman MM, Spritzler J, Coombs RW, Fox L, Schock B, Yen-Lieberman B, Johnson R, Mildvan D, Parekh N; AIDS Clinical Trials Group 334 Investigators. Calabrese LH, et al. Among authors: lederman mm. J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):356-62. doi: 10.1097/00126334-200204010-00005. J Acquir Immune Defic Syndr. 2002. PMID: 11917239 Clinical Trial.
450 results